Active Biotech AB Interim report January - June 2016
August 11 2016 - 2:30AM
Laquinimod
-
The clinical trials CONCERTO, ARPEGGIO and
LEGATO-HD are progressing according to plan
-
The study results from both the pivotal clinical
Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis
(RRMS) and the Phase 2 study ARPEGGIO, evaluating laquinimod for
the treatment of primary progressive multiple sclerosis (PPMS), are
expected in the first half of 2017
-
Positive results concerning laquinimod were
presented at the 68th AAN Annual Meeting (American Academy of
Neurology), held in Vancouver, Canada, on April 15-21, 2016
Tasquinimod
ANYARA, Paquinimod (57-57) and
SILC (ISI)
Financial
summary
SEK M |
Q2 |
Q1-Q2 |
Full
Year |
|
2016 |
2015 |
2016 |
2015 |
2015 |
|
|
|
|
|
|
Net
sales |
3.9 |
3.2 |
7.9 |
6.1 |
16.3 |
Operating
loss |
-14.5 |
-70.1 |
-30.6 |
-127.5 |
-177.9 |
Loss for
the period |
-15.5 |
-71.4 |
-32.3 |
-129.3 |
-193.5 |
Loss per
share, before and after dilution (SEK) |
-0.17 |
-0.79 |
-0.36 |
-1.44 |
-2.15 |
Cash and
cash equivalents (at the end of the period) |
|
|
57.4 |
186.6 |
103.6 |
-
Refocusing of the company is completed,
operating costs reduced by 71% (SEK 95.2 M) compared with
2015
-
The number of employees will be reduced from 56
(June 2015) to 17 by the end of the third quarter of 2016
-
Operations are progressing according to plan
pending the Phase 3 results for laquinimod in the first half of
2017
For further
information, please contact:
Tomas
Leanderson, President and CEO
Tel: +46 46 19 20 95
Hans Kolam, CFO
Tel: +46 46 19 20 44
|
Active
Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 05
|
The report is also available at
www.activebiotech.com.
Active Biotech AB (publ) Interim
Report January - June 2016
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
HUG#2034058
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024